

# Ravi Varadhan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6431359/publications.pdf>

Version: 2024-02-01

134  
papers

6,892  
citations

87401

40  
h-index

75989

78  
g-index

136  
all docs

136  
docs citations

136  
times ranked

11094  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Small Domain Estimation via Compromise Regression Weights. <i>Journal of the American Statistical Association</i> , 2023, 118, 2793-2809.	1.8	0
2	Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1340-1349.	0.5	5
3	Statins and Cognitive Decline in the Cardiovascular Health Study: A Comparison of Different Analytical Approaches. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 994-1001.	1.7	4
4	Risk Factors for Nonresilient Outcomes in Older Adults After Total Knee Replacement. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 1915-1922.	1.7	6
5	Life expectancy estimates based on comorbidities and frailty to inform preventive care. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 99-109.	1.3	15
6	Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 260-269.	0.2	4
7	Diminished ovarian reserve in young women with sickle cell anemia. <i>Blood</i> , 2022, 139, 1111-1115.	0.6	17
8	SHBG, Bone Mineral Density, and Physical Function Among Injection Drug Users With and Without HIV and HCV. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2971-e2981.	1.8	2
9	The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. <i>Science Advances</i> , 2022, 8, eabl8952.	4.7	7
10	Cortisol and Dehydroepiandrosterone Response to Adrenocorticotrophic Hormone and Frailty in Older Women. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 901-905.	1.7	9
11	2015-2016 Normative Data for the 3-m Usual Walk, Five Repeated Chair Stands, and Static Balance Components of the SPPB Among U.S. Older Adults Across Two Nationally Representative Data Sets: NSHAP and NHATS. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, S299-S312.	2.4	5
12	The physical frailty syndrome as a transition from homeostatic symphony to cacophony. <i>Nature Aging</i> , 2021, 1, 36-46.	5.3	210
13	Large Granular Lymphocytosis With Cytopenias After Allogeneic Blood or Marrow Transplantation: Clinical Characteristics and Response to Immunosuppressive Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 260.e1-260.e6.	0.6	2
14	Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2021, 5, 1360-1368.	2.5	39
15	Intrinsic Capacity as a Determinant of Physical Resilience in Older Adults. <i>Journal of Nutrition, Health and Aging</i> , 2021, 25, 1006-1011.	1.5	31
16	Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Keynote and panel discussion on communicating heterogeneous treatment effects across populations. <i>Pharmaceutical Statistics</i> , 2021, 20, 965-978.	0.7	0
17	Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. <i>British Journal of Haematology</i> , 2021, 193, 1142-1150.	1.2	21
18	Geographic Regions Enriched with Frail Older Adults. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 2609-2610.e2.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Lasso estimation of hierarchical interactions for analyzing heterogeneity of treatment effect. <i>Statistics in Medicine</i> , 2021, 40, 5417-5433.	0.8	5
20	Abstract 903: Circulating inflammatory proteins associated with mortality from causes other than the index cancer in older adult cancer survivors in the atherosclerosis risk in communities study. , 2021, , .		0
21	Addressing and communicating heterogeneous treatment effects for patient subpopulations: Challenges and opportunities. <i>Pharmaceutical Statistics</i> , 2021, 20, 920-922.	0.7	0
22	Longitudinal Changes in Sex Hormoneâ€“Binding Globulin in Men With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1178-1186.	0.9	6
23	Is Colorectal Cancer Screening Absolutely Beneficial for Older Adults?. <i>JAMA Oncology</i> , 2021, 7, 1728.	3.4	0
24	Treatment of Acute Pain in Adults With Sickle Cell Disease in an Infusion Center Versus the Emergency Department. <i>Annals of Internal Medicine</i> , 2021, 174, 1207-1213.	2.0	16
25	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 863.e1-863.e5.	0.6	4
26	The Presence of SETBP1, RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents. <i>Blood</i> , 2021, 138, 1520-1520.	0.6	0
27	Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. , 2021, 9, e003894.		50
28	Principles and Issues for Physical Frailty Measurement and Its Clinical Application. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1107-1112.	1.7	24
29	Individualized treatment effects with censored data via fully nonparametric Bayesian accelerated failure time models. <i>Biostatistics</i> , 2020, 21, 50-68.	0.9	40
30	Segal and Varadhan Respond to â€œEstimation With Claims-Based Frailty Indexesâ€• <i>American Journal of Epidemiology</i> , 2020, 189, 372-372.	1.6	0
31	Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 502-508.	2.0	9
32	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. <i>Annals of Internal Medicine</i> , 2020, 172, 35.	2.0	203
33	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration. <i>Annals of Internal Medicine</i> , 2020, 172, W1.	2.0	83
34	A Phase 1 Study of IRX195183, a RAR $\alpha$ -Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML. <i>Frontiers in Oncology</i> , 2020, 10, 587062.	1.3	3
35	Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. <i>Cmaj</i> , 2020, 192, E901-E906.	0.9	271
36	Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2306-2310.	2.0	8

#	ARTICLE	IF	CITATIONS
37	Derivation of a measure of physiological multisystem dysregulation: Results from WHAS and health ABC. <i>Mechanisms of Ageing and Development</i> , 2020, 188, 111258.	2.2	9
38	Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1679-1688.	2.0	25
39	A Machine Learning Approach Deciphers the Effects of Immune Parameters on Clinical Outcomes after HLA-Haploidentical and HLA-Matched Allogeneic Bone Marrow Transplantation with Posttransplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S30-S31.	2.0	1
40	RELATIONSHIP OF PHYSICAL FRAILITY TO PHOSPHOCREATINE RECOVERY IN MUSCLE AFTER MILD EXERCISE STRESS IN THE OLDEST-OLD WOMEN. <i>Journal of Frailty &amp; Aging,the</i> , 2019, 8, 1-7.	0.8	8
41	If we recognize heterogeneity of treatment effect can we lessen waste?. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1143-1145.	0.6	1
42	A Socratic Inquiry Into the Nature of Frailty. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 2455-2457.	1.3	0
43	Frailty Among Older Adults With Acute Myocardial Infarction and Outcomes From Percutaneous Coronary Interventions. <i>Journal of the American Heart Association</i> , 2019, 8, e013686.	1.6	55
44	R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1261-1265.	0.6	14
45	Damped Anderson Acceleration With Restarts and Monotonicity Control for Accelerating EM and EM-like Algorithms. <i>Journal of Computational and Graphical Statistics</i> , 2019, 28, 834-846.	0.9	40
46	Allogeneic Transplantation in Septuagenarians Using Post-Transplant Cyclophosphamide (PTCy): Similar Outcomes to Younger Patients Except for Higher Late Non-Relapse Mortality (NRM). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S33-S34.	2.0	0
47	Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. <i>Blood Advances</i> , 2019, 3, 2608-2616.	2.5	20
48	Statistical Code for Clinical Research Papers. <i>Annals of Internal Medicine</i> , 2019, 170, 79.	2.0	2
49	Association of Frailty With Recovery From Disability Among Community-Dwelling Older Adults: Results From Two Large U.S. Cohorts. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 575-581.	1.7	18
50	Considerations when assessing heterogeneity of treatment effect in patient-centered outcomes research. <i>Journal of Clinical Epidemiology</i> , 2018, 100, 22-31.	2.4	27
51	Claims-Based Frailty Index Options. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 988-988.	1.7	3
52	Bayesian bivariate subgroup analysis for risk-benefit evaluation. <i>Health Services and Outcomes Research Methodology</i> , 2018, 18, 244-264.	0.8	2
53	Frailty, Inflammation, and Waitlist Mortality among Patients with End-Stage Renal Disease on the Kidney Transplant Waitlist. <i>Transplantation</i> , 2018, 102, S162.	0.5	0
54	Increased acute care utilization in a prospective cohort of adults with sickle cell disease. <i>Blood Advances</i> , 2018, 2, 2412-2417.	2.5	31

#	ARTICLE	IF	CITATIONS
55	Frailty, Inflammatory Markers, and Waitlist Mortality Among Patients With End-stage Renal Disease in a Prospective Cohort Study. <i>Transplantation</i> , 2018, 102, 1740-1746.	0.5	97
56	Engaging clinicians and patients to assess and improve frailty measurement in adults with end stage renal disease. <i>BMC Nephrology</i> , 2018, 19, 8.	0.8	33
57	Can a Link Be Found Between Physical Resilience and Frailty in Older Adults by Studying Dynamical Systems?. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1455-1458.	1.3	52
58	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2056-2064.	2.0	32
59	Patient Satisfaction of Care in the Treatment of Vaso-Occlusive Crises: A Comparison of Emergency Department and Infusion Centers in the Escaped Study. <i>Blood</i> , 2018, 132, 314-314.	0.6	0
60	A Five Fold Decrease in Admissions for Uncomplicated Vaso-Occlusive Crisis and Other Benefits from Care in Infusion Clinics: Results from the Escaped Trial. <i>Blood</i> , 2018, 132, 853-853.	0.6	1
61	Methodologic approach for the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 333S-347S.	2.2	140
62	Frailty and Cause-Specific Hospitalization Among Persons Aging With HIV Infection and Injection Drug Use. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, glw142.	1.7	18
63	Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 612-617.	2.0	17
64	Integrating Frailty Research into the Medical Specialties Report from a U13 Conference. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2134-2139.	1.3	71
65	A Quiescent Phase in Human Mortality? Exploring the Ages of Least Vulnerability. <i>Demography</i> , 2017, 54, 1097-1118.	1.2	11
66	Development of a Claims-based Frailty Indicator Anchored to a Well-established Frailty Phenotype. <i>Medical Care</i> , 2017, 55, 716-722.	1.1	169
67	Report: NIA Workshop on Measures of Physiologic Resiliencies in Human Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 980-990.	1.7	111
68	Factors Associated With Ischemic Stroke Survival and Recovery in Older Adults. <i>Stroke</i> , 2017, 48, 1818-1826.	1.0	85
69	Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S106.	2.0	3
70	Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. <i>Blood</i> , 2017, 129, 1389-1393.	0.6	69
71	Dementia and Alzheimer's Disease among Older Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1575-1583.	3.0	43
72	EXTERNAL VALIDATION OF THE CLAIMS-BASED FRAILITY INDEX IN THE NATIONAL HEALTH AND AGING TRENDS STUDY COHORT. <i>American Journal of Epidemiology</i> , 2017, 186, 745-747.	1.6	47

#	ARTICLE	IF	CITATIONS
73	Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature. <i>Leukemia Research</i> , 2017, 61, 25-32.	0.4	12
74	Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1903-1909.	2.0	14
75	Cross-design synthesis for extending the applicability of trial evidence when treatment effect is heterogenous: Part II. Application and external validation. <i>Communications in Statistics Case Studies Data Analysis and Applications</i> , 2017, 3, 7-20.	0.3	3
76	Predictors of anemia in preschool children: Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 402S-415S.	2.2	101
77	The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient. <i>Blood</i> , 2017, 130, 849-849.	0.6	1
78	Bayesian analysis of heterogeneous treatment effects for patient-centered outcomes research. <i>Health Services and Outcomes Research Methodology</i> , 2016, 16, 213-233.	0.8	37
79	Physical Frailty Assessment in Older Women: Can Simplification Be Achieved Without Loss of Syndrome Measurement Validity?. <i>American Journal of Epidemiology</i> , 2016, 183, 1037-1044.	1.6	13
80	Treatment effect heterogeneity for univariate subgroups in clinical trials: Shrinkage, standardization, or else. <i>Biometrical Journal</i> , 2016, 58, 133-153.	0.6	11
81	Declines and Impairment in Executive Function Predict Onset of Physical Frailty. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 1624-1630.	1.7	63
82	Frailty assessment instruments: Systematic characterization of the uses and contexts of highly-cited instruments. <i>Ageing Research Reviews</i> , 2016, 26, 53-61.	5.0	575
83	Race and fall risk: data from the National Health and Aging Trends Study (NHATS). <i>Age and Ageing</i> , 2016, 45, 120-127.	0.7	43
84	Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. <i>Leukemia</i> , 2016, 30, 1916-1920.	3.3	79
85	The Use of Post-Transplantation Cyclophosphamide after Myeloablative, HLA-Matched Allogeneic Bone Marrow Transplantation Minimizes the Need for Additional Immunosuppression. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S46-S47.	2.0	0
86	Cross-design synthesis for extending the applicability of trial evidence when treatment effect is heterogeneous: Part I. Methodology. <i>Communications in Statistics Case Studies Data Analysis and Applications</i> , 2016, 2, 112-126.	0.3	3
87	Acute Care Utilization Is More Common in Patients with Sickle Cell Disease Who Have Chronic Complications and Chronic Pain: A Preliminary Report from the Escaped Trial. <i>Blood</i> , 2016, 128, 2490-2490.	0.6	1
88	Comparison of Simple Versus Performance-Based Fall Prediction Models. <i>Gerontology and Geriatric Medicine</i> , 2015, 1, 233372141558485.	0.8	14
89	Frailty, Inflammation, and Mortality Among Persons Aging With HIV Infection and Injection Drug Use. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015, 70, 1542-1547.	1.7	76
90	Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer. <i>BMC Medicine</i> , 2015, 13, 250.	2.3	29

#	ARTICLE	IF	CITATIONS
91	Financial strain is associated with increased oxidative stress levels: The Women's Health and Aging Studies. <i>Geriatric Nursing</i> , 2015, 36, S33-S37.	0.9	20
92	Frailty in Older Adults: A Nationally Representative Profile in the United States. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015, 70, 1427-1434.	1.7	518
93	Topical intranasal corticosteroids and growth velocity in children: a meta-analysis. <i>International Forum of Allergy and Rhinology</i> , 2015, 5, 95-103.	1.5	31
94	Related Nonmyeloablative Haploidentical (mini-haplo) Blood or Marrow Transplantation (BMT) with High-Dose Post-Transplant Cyclophosphamide (PTCy) for Acute Myeloid Leukemia (AML): Donor Age Impacts Outcome. <i>Blood</i> , 2015, 126, 151-151.	0.6	4
95	Multimorbidity and Evidence Generation. <i>Journal of General Internal Medicine</i> , 2014, 29, 653-660.	1.3	54
96	What Is Missing in the Validation of Frailty Instruments?. <i>Journal of the American Medical Directors Association</i> , 2014, 15, 141-142.	1.2	47
97	Standardization for Subgroup Analysis in Randomized Controlled Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 154-167.	0.4	24
98	Semicompeting risks in aging research: methods, issues and needs. <i>Lifetime Data Analysis</i> , 2014, 20, 538-562.	0.4	18
99	Simple Biologically Informed Inflammatory Index of Two Serum Cytokines Predicts 10 Year All-Cause Mortality in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69A, 165-173.	1.7	197
100	Benefits and harms of roflumilast in moderate to severe COPD. <i>Thorax</i> , 2014, 69, 616-622.	2.7	44
101	Analyzing feed-forward loop relationship in aging phenotypes: Physical activity and physical performance. <i>Mechanisms of Ageing and Development</i> , 2014, 141-142, 5-11.	2.2	8
102	A general binomial regression model to estimate standardized risk differences from binary response data. <i>Statistics in Medicine</i> , 2013, 32, 808-821.	0.8	26
103	Rationalizing Prescribing for Older Patients with Multimorbidity: Considering Time to Benefit. <i>Drugs and Aging</i> , 2013, 30, 655-666.	1.3	109
104	Assessing heterogeneity of treatment effect in a clinical trial with the proportional interactions model. <i>Statistics in Medicine</i> , 2013, 32, 4906-4923.	0.8	26
105	Model selection in competing risks regression. <i>Statistics in Medicine</i> , 2013, 32, 3077-3088.	0.8	105
106	A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 818-825.	2.4	101
107	Frailty Status and Altered Glucose-Insulin Dynamics. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2012, 67, 1300-1306.	1.7	100
108	Patterns of 12-Year Change in Physical Activity Levels in Community-Dwelling Older Women: Can Modest Levels of Physical Activity Help Older Women Live Longer?. <i>American Journal of Epidemiology</i> , 2012, 176, 534-543.	1.6	70



#	ARTICLE	IF	CITATIONS
109	estimating Metabolic Rate in Old Old Women with and without Frailty: Variability and Estimation of Energy Requirements. Journal of the American Geriatrics Society, 2012, 60, 1695-1700.	1.3	24
110	Assessing the applicability of trial evidence to a target sample in the presence of heterogeneity of treatment effect. Pharmacoepidemiology and Drug Safety, 2012, 21, 121-129.	0.9	9
111	Circulating selenium and carboxymethyl-lysine, an advanced glycation endproduct, are independent predictors of anemia in older community-dwelling adults. Nutrition, 2012, 28, 762-766.	1.1	13
112	Endogenous Secretory Receptor for Advanced Glycation End Products and Chronic Kidney Disease in the Elderly Population. American Journal of Nephrology, 2011, 33, 313-318.	1.4	10
113	Evaluating Health Outcomes in the Presence of Competing Risks. Medical Care, 2010, 48, S96-S105.	1.1	179
114	Central Nervous System Medication Changes and Falls in Nursing Home Residents. Geriatric Nursing, 2009, 30, 334-340.	0.9	18
115	Nonlinear Multisystem Physiological Dysregulation Associated With Frailty in Older Women: Implications for Etiology and Treatment. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 1049-1057.	1.7	403
116	Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. Aging Clinical and Experimental Research, 2009, 21, 182-190.	1.4	97
117	BB: An R Package for Solving a Large System of Nonlinear Equations and for Optimizing a High-Dimensional Nonlinear Objective Function. Journal of Statistical Software, 2009, 32, .	1.8	102
118	Physiological Complexity Underlying Heart Rate Dynamics and Frailty Status in Community-dwelling Older Women. Journal of the American Geriatrics Society, 2008, 56, 1698-1703.	1.3	80
119	Simple and Globally Convergent Methods for Accelerating the Convergence of Any EM Algorithm. Scandinavian Journal of Statistics, 2008, 35, 335-353.	0.9	243
120	Opinion section on frailty. Mechanisms of Ageing and Development, 2008, 129, 665.	2.2	3
121	Circulating oxidized low-density lipoproteins are associated with overweight, obesity, and low serum carotenoids in older community-dwelling women. Nutrition, 2008, 24, 964-968.	1.1	17
122	Higher Levels and Blunted Diurnal Variation of Cortisol in Frail Older Women. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 190-195.	1.7	138
123	Circulating oxidized low-density lipoproteins are associated with overweight, obesity, and low serum carotenoids in older community-dwelling women. FASEB Journal, 2008, 22, 924.4.	0.2	0
124	Oxidative protein damage is associated with poor grip strength among older women living in the community. Journal of Applied Physiology, 2007, 103, 17-20.	1.2	174
125	Oxidative Stress and Severe Walking Disability among Older Women. American Journal of Medicine, 2007, 120, 1084-1089.	0.6	112
126	Oxidative Stress Is Associated with Greater Mortality in Older Women Living in the Community. Journal of the American Geriatrics Society, 2007, 55, 1421-1425.	1.3	43



#	ARTICLE	IF	CITATIONS
127	Low serum selenium concentrations are associated with poor grip strength among older women living in the community. <i>BioFactors</i> , 2007, 29, 37-44.	2.6	52
128	Oxidative protein damage is associated with poor grip strength among older women living in the community. <i>FASEB Journal</i> , 2007, 21, A685.	0.2	0
129	Association Between Reduced Heart Rate Variability and Cognitive Impairment in Older Disabled Women in the Community: Women's Health and Aging Study I. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1751-1757.	1.3	108
130	Low serum carotenoids and development of severe walking disability among older women living in the community: the Women's Health and Aging Study I. <i>Age and Ageing</i> , 2006, 36, 62-67.	0.7	50
131	Revealing and Addressing Length Bias and Heterogeneous Effects in Frequency Case-Crossover Studies. <i>American Journal of Epidemiology</i> , 2004, 159, 596-602.	1.6	4
132	Methodology for Evaluating a Partially Controlled Longitudinal Treatment Using Principal Stratification, With Application to a Needle Exchange Program. <i>Journal of the American Statistical Association</i> , 2004, 99, 239-249.	1.8	40
133	Relationships between brachial-ankle pulse wave velocity and conventional atherosclerotic risk factors in community-dwelling people. <i>Preventive Medicine</i> , 2004, 39, 1135-1142.	1.6	29
134	Limitations of ROI Testing for Venting Design: Description of an Alternative Approach Based on Attainment of a Critical Pore-Gas Velocity in Contaminated Media. <i>Ground Water Monitoring and Remediation</i> , 2001, 21, 97-114.	0.6	8